CN112912141B - 用于树突棘生成的肌成束蛋白结合化合物 - Google Patents

用于树突棘生成的肌成束蛋白结合化合物

Info

Publication number
CN112912141B
CN112912141B CN201980070624.1A CN201980070624A CN112912141B CN 112912141 B CN112912141 B CN 112912141B CN 201980070624 A CN201980070624 A CN 201980070624A CN 112912141 B CN112912141 B CN 112912141B
Authority
CN
China
Prior art keywords
compound
formula
pharmaceutically acceptable
fascin
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980070624.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN112912141A (zh
Inventor
S·T·撒拉弗
V·F·西蒙
P·W·范德克里什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spirogynex
Original Assignee
Spirogynex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spirogynex filed Critical Spirogynex
Publication of CN112912141A publication Critical patent/CN112912141A/zh
Application granted granted Critical
Publication of CN112912141B publication Critical patent/CN112912141B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980070624.1A 2018-08-27 2019-08-27 用于树突棘生成的肌成束蛋白结合化合物 Active CN112912141B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862723381P 2018-08-27 2018-08-27
US62/723,381 2018-08-27
US201862726904P 2018-09-04 2018-09-04
US62/726,904 2018-09-04
US201862785435P 2018-12-27 2018-12-27
US62/785,435 2018-12-27
PCT/US2019/048408 WO2020046991A1 (en) 2018-08-27 2019-08-27 Fascin binding compounds for spinogenesis

Publications (2)

Publication Number Publication Date
CN112912141A CN112912141A (zh) 2021-06-04
CN112912141B true CN112912141B (zh) 2026-03-31

Family

ID=69644570

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980070624.1A Active CN112912141B (zh) 2018-08-27 2019-08-27 用于树突棘生成的肌成束蛋白结合化合物

Country Status (7)

Country Link
US (2) US20210330646A1 (https=)
EP (1) EP3843846A4 (https=)
JP (2) JP7583710B2 (https=)
CN (1) CN112912141B (https=)
AU (1) AU2019329835B2 (https=)
CA (1) CA3110877A1 (https=)
WO (1) WO2020046991A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018312558B2 (en) 2017-08-02 2022-09-29 Spinogenix, Inc. Benzothiazole and related compounds
HUE072464T2 (hu) 2019-01-31 2025-11-28 Spinogenix Inc Spinogenézis egy promoterének szilárd formái
CA3189027A1 (en) 2020-07-11 2022-01-20 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
EP4294391A4 (en) * 2021-02-22 2024-12-18 Spinogenix, Inc. METHODS OF TREATING SPINAL CORD INJURY OR DAMAGE
JP2024510632A (ja) * 2021-03-23 2024-03-08 スピノジェニックス， インコーポレイテッド スパイン形成のためのある特定のファスシン結合化合物
WO2024211310A1 (en) * 2023-04-03 2024-10-10 Spinogenix, Inc. Methods of dosing spinogenic compounds
CN121773104A (zh) * 2023-06-30 2026-03-31 北京双鹤润创科技有限公司 肌成束蛋白抑制剂
WO2025184576A1 (en) * 2024-02-29 2025-09-04 Spinogenix, Inc. Methods for prevention and treatment of depression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736202A (zh) * 2012-08-22 2015-06-24 康奈尔大学 用于抑制肌成束蛋白的方法
CN106232583A (zh) * 2014-02-20 2016-12-14 康奈尔大学 用于抑制肌成束蛋白的化合物和方法
WO2017120198A1 (en) * 2016-01-05 2017-07-13 The Regents Of The University Of California Benzothiazole amphiphiles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
AU2012239977B9 (en) 2011-04-07 2016-11-17 Sloan-Kettering Institute For Cancer Research Migrastatins and uses thereof
WO2013013240A2 (en) 2011-07-21 2013-01-24 Theracrine, Inc. Macrocyclic compounds and related compositons and methods of use
EP2755974A1 (en) * 2011-09-14 2014-07-23 Proximagen Limited New enzyme inhibitor compounds
TWI586367B (zh) 2016-03-28 2017-06-11 蔡懷楨 磷酸甘油酯激酶增加神經突生長及／或治療神經性疾病的用途
AU2018312558B2 (en) 2017-08-02 2022-09-29 Spinogenix, Inc. Benzothiazole and related compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736202A (zh) * 2012-08-22 2015-06-24 康奈尔大学 用于抑制肌成束蛋白的方法
CN106232583A (zh) * 2014-02-20 2016-12-14 康奈尔大学 用于抑制肌成束蛋白的化合物和方法
WO2017120198A1 (en) * 2016-01-05 2017-07-13 The Regents Of The University Of California Benzothiazole amphiphiles

Also Published As

Publication number Publication date
WO2020046991A1 (en) 2020-03-05
CA3110877A1 (en) 2020-03-05
JP2025016676A (ja) 2025-02-04
US20210330646A1 (en) 2021-10-28
US20240423962A1 (en) 2024-12-26
EP3843846A4 (en) 2022-09-07
CN112912141A (zh) 2021-06-04
AU2019329835B2 (en) 2025-05-29
JP7583710B2 (ja) 2024-11-14
JP2021535159A (ja) 2021-12-16
AU2019329835A1 (en) 2021-04-15
EP3843846A1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
CN112912141B (zh) 用于树突棘生成的肌成束蛋白结合化合物
CN104127434B (zh) 使用唑尼沙胺和阿坎酸治疗阿尔茨海默病和相关病症的组合组合物
Sani et al. Distribution, progression and chemical composition of cortical amyloid-β deposits in aged rhesus monkeys: similarities to the human
US20190381007A1 (en) (3ar)-1,3a,8-trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
US12486287B2 (en) Solid forms of a promoter of spinogenesis
HK1248153A1 (zh) 用於治疗衰老相关的损伤的方法和组合物
US20080242608A1 (en) Methods and compositions for treating and preventing neurologic disorders
JP2019123748A (ja) アミロイドβのガランタミンクリアランス
Yalcin et al. Effects of 5, 7-dihydroxytryptamine lesion of the dorsal raphe nucleus on the antidepressant-like action of tramadol in the unpredictable chronic mild stress in mice
KR20190102181A (ko) 알츠하이머병의 치료를 위한 항-a베타 원시섬유 항체 및 베타-세크레타제 bace1 억제제를 포함하는 조성물
Sayas Tau-based therapies for Alzheimer’s disease: Promising novel neuroprotective approaches
JP2016523969A (ja) エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法
CN114929742A (zh) 用三叶因子家族成员2调节剂治疗衰老相关损伤的方法和组合物
Horowitz et al. Characterization of fluoxetine plus olanzapine treatment in rats: A behavior, endocrine, and immediate‐early gene expression analysis
US20240180920A1 (en) Certain fascin binding compounds for spinogenesis
CA3128280C (en) Solid forms of a promoter of spinogenesis
AU2024244089A1 (en) Methods of dosing spinogenic compounds
CN117320713A (zh) 用于树突棘生成的某些肌成束蛋白结合化合物
HK40063672B (en) Solid forms of a promoter of spinogenesis
HK40063672A (en) Solid forms of a promoter of spinogenesis
WO2025184576A1 (en) Methods for prevention and treatment of depression
CN121604971A (zh) 用于治疗与焦虑症相关的认知障碍的hip/pap蛋白或其衍生物
van Kammen et al. Predicting duration of clinical stability following haloperidol withdrawal in schizophrenia
Sundaram Alzheimer's Disease New Insight Into an Aging Riddle
JP2000239181A (ja) 細胞保護剤及び細胞保護作用物質の選別方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant